A Comparison of SARS-COV-2 Neutralizing Antibody Therapies in High-Risk Patients with Mild to Moderate COVID-19 Disease at a Single Academic Hospital

Background: Bamlanivimab and casirivimab/imdevimab are recombinant neutralizing monoclonal antibodies that decrease viral load in patients with coronavirus disease 2019 (COVID-19) and can decrease hospitalizations. Few data exist comparing these two therapies. Objective: Our aim was to compare the e...

Descripción completa

Detalles Bibliográficos
Autores principales: Farcy, David A., Dalley, Michael T., Miro, Grethel, Swalley, Paige, Sherman, Dana, Nash, Joel, Jodoin, Kathleen, Cubeddu, Luigi X., Zitek, Tony, Goldszer, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2022
Materias:
Pharmacology in Emergency Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8279938/
https://www.ncbi.nlm.nih.gov/pubmed/34489146
http://dx.doi.org/10.1016/j.jemermed.2021.07.025

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8279938/
https://www.ncbi.nlm.nih.gov/pubmed/34489146
http://dx.doi.org/10.1016/j.jemermed.2021.07.025

Ejemplares similares